Skip to main content
Skip to footer content
Why Tiprelestat
About
Career
News
Archived news
2020-12
:
Clinical Trial Phase I “Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects” completed.
2019-03
:
tiakis (formerly Proteo Biotech AG) Elafin Enters the Clinic For Subcutaneous Use In Pulmonary Arterial Hypertension
2019-02
:
tiakis receives GLP Certificate from Competent Authority
2018-07
:
New mechanism of Elafin to prevent lung injury in mechanically ventilated newborns